Skip to content
10-Q

Quarterly Report

Relmada Therapeutics, Inc. RLMD

0001213900-26-055059

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 104.89M sh
Shares Diluted Q1 2026 · Mar 31, 2026 86.6M sh
Shares Diluted Q1 2026 · Mar 31, 2025 30.41M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $3.36M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$15.07M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$18.07M
Short Term Investments Q1 2026 · Mar 31, 2026 $224.19M
Short Term Investments Q1 2026 · Dec 31, 2025 $89.51M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $9.78M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $3.5M
Stockholders Equity Q1 2026 · Mar 31, 2026 $218.73M
Stockholders Equity Q1 2026 · Dec 31, 2025 $86.51M
Stockholders Equity Q1 2026 · Mar 31, 2025 $22.44M
Stockholders Equity Q1 2026 · Dec 31, 2024 $35.52M
Current Liabilities Q1 2026 · Mar 31, 2026 $12.89M
Current Liabilities Q1 2026 · Dec 31, 2025 $6.43M
Total Liabilities Q1 2026 · Mar 31, 2026 $16.63M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.49M
Current Assets Q1 2026 · Mar 31, 2026 $235.34M
Current Assets Q1 2026 · Dec 31, 2025 $93.98M
Total Assets Q1 2026 · Mar 31, 2026 $235.36M
Total Assets Q1 2026 · Dec 31, 2025 $94M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.22
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.58
Eps Basic Q1 2026 · Mar 31, 2026 −$0.22
Eps Basic Q1 2026 · Mar 31, 2025 −$0.58
Sga Expense Q1 2026 · Mar 31, 2026 $11.37M
Sga Expense Q1 2026 · Mar 31, 2025 $6.27M
Rd Expense Q1 2026 · Mar 31, 2026 $8.09M
Rd Expense Q1 2026 · Mar 31, 2025 $11.95M
Net Income Q1 2026 · Mar 31, 2026 −$19.05M
Net Income Q1 2026 · Mar 31, 2025 −$17.56M
Operating Income Q1 2026 · Mar 31, 2026 −$19.46M
Operating Income Q1 2026 · Mar 31, 2025 −$18.22M